Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma

H Zhang, K Spencer, SK Burley, XFS Zheng - Drug discovery today, 2021 - Elsevier
Highlights•AR is an oncogenic driver of hepatocellular carcinoma.•AR-targeted therapy is
limited by feedback activation of AKT-mTOR pathway.•Co-targeting of mTORC1 and AR may …
被引用次数：22 相关文章

Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma

H Zhang, K Spencer, SK Burley… - Drug discovery …, 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and a leading
cause of cancer deaths worldwide. HCC is a male-dominant cancer with a male: female ratio …

Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma

H Zhang, K Spencer, SK Burley… - Drug Discovery …, 2021 - researchwithrutgers.com
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and a leading
cause of cancer deaths worldwide. HCC is a male-dominant cancer with a male: female ratio …

Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma.

H Zhang, K Spencer, SK Burley… - Drug Discovery Today, 2021 - europepmc.org
HCC is the predominant form of liver cancer and is the fourth leading cause of cancerrelated
deaths worldwide [1]. In contrast to the decreasing trend in overall cancer mortality, HCC has …
[HTML] nih.gov

[HTML][HTML] Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma

H Zhang, K Spencer, SK Burley, XFS Zheng - Drug discovery today, 2021 - ncbi.nlm.nih.gov
HCC is the predominant form of liver cancer and is the fourth leading cause of cancerrelated
deaths worldwide [1]. In contrast to the decreasing trend in overall cancer mortality, HCC has …